Evidence method
Level · gp.fundamentals.capex_revenue_ratio
23.99% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
CRNX · Jun 30, 2023
Crinetics Pharmaceuticals, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000950170-23-039350General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-4629.05% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
125.06% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-5363.87% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
4113.36% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
1029.86% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History14 statesSelf-history eligible
Sep 30, 20190/6 normalizedLevel 3Dec 31, 20190/6 normalizedLevel 3Mar 31, 20200/6 normalizedLevel 3Dec 31, 20200/6 normalizedLevel 3Mar 31, 20235/6 normalizedLevel 3Jun 30, 20236/6 normalizedLevel 3Sep 30, 20236/6 normalizedLevel 3Mar 31, 20246/6 normalizedLevel 3Jun 30, 20246/6 normalizedLevel 3Mar 31, 20256/6 normalizedLevel 3Jun 30, 20256/6 normalizedLevel 3Dec 31, 20256/8 normalizedLevel 3Mar 31, 20266/8 normalizedLevel 3Jun 30, 20266/8 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 0.60%
- Current
- 23.99%
- Delta
- 23.39%
- Previous
- -1519.90%
- Current
- -4629.05%
- Delta
- -3109.15%
- Previous
- -14.44%
- Current
- 125.06%
- Delta
- 139.49%
- Previous
- -1790.89%
- Current
- -5363.87%
- Delta
- -3572.97%
- Previous
- 1435.91%
- Current
- 4113.36%
- Delta
- 2677.45%
- Previous
- 302.20%
- Current
- 1029.86%
- Delta
- 727.66%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · CRNX Fundamental State →Transitioned To · CRNX PROFITABILITY_DECREASED →Transitioned To · CRNX R_AND_D_INTENSITY_INCREASED →Transitioned To · CRNX SBC_INTENSITY_INCREASED →Transitioned To · CRNX historical state 2023-03-31 →Transitioned To · CRNX CAPEX_INTENSITY_INCREASED →Transitioned To · CRNX CASH_GENERATION_DECREASED →Transitioned To · CRNX GROWTH_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.